- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00113269
Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients (INTAC)
Phase 4, Randomized, Open-label, Comparative, Multicenter Study to Assess the Safety and Efficacy of Induction Agents, Alemtuzumab, Basiliximab or Rabbit Anti-thymocyte Globulin in Combination With Tacrolimus, MMF, and a Rapid Steroid Withdrawal in Renal Transplant Recipients
Przegląd badań
Status
Warunki
Szczegółowy opis
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 4
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35294
-
-
California
-
Los Angeles, California, Stany Zjednoczone, 90057
-
Palo Alto, California, Stany Zjednoczone, 94304
-
San Diego, California, Stany Zjednoczone, 92123
-
San Francisco, California, Stany Zjednoczone, 94115
-
San Francisco, California, Stany Zjednoczone, 94143
-
-
Colorado
-
Denver, Colorado, Stany Zjednoczone, 80262
-
-
District of Columbia
-
Washington, District of Columbia, Stany Zjednoczone, 20010
-
Washington, District of Columbia, Stany Zjednoczone, 20007
-
-
Florida
-
Miami, Florida, Stany Zjednoczone, 33136
-
Tampa, Florida, Stany Zjednoczone, 33066
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60611
-
Chicago, Illinois, Stany Zjednoczone, 60612
-
-
New Jersey
-
Livingston, New Jersey, Stany Zjednoczone, 07039
-
New Brunswick, New Jersey, Stany Zjednoczone, 08901
-
-
New York
-
Hawthorne, New York, Stany Zjednoczone, 10532
-
New York, New York, Stany Zjednoczone, 10032
-
New York, New York, Stany Zjednoczone, 10029
-
-
North Carolina
-
Chapel Hill, North Carolina, Stany Zjednoczone, 27599
-
Durham, North Carolina, Stany Zjednoczone, 27710
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45267
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone, 97239
-
-
Pennsylvania
-
Danville, Pennsylvania, Stany Zjednoczone, 17822
-
Harrisburg, Pennsylvania, Stany Zjednoczone, 17105
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone, 29425
-
-
Texas
-
San Antonio, Texas, Stany Zjednoczone, 78229
-
-
Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84132
-
-
Wisconsin
-
Madison, Wisconsin, Stany Zjednoczone, 53792
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53226
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Recipient of a primary or re-transplanted deceased donor kidney or a primary or re-transplanted non-human leukocyte antigen (HLA) living donor kidney (ie., HLA identical or 0 antigen mismatch deceased donor kidneys are allowed).
Exclusion Criteria:
- Patient has previously received an organ transplant other than a kidney
- Patient receiving chronic steroid therapy at time of transplant
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Alemtuzumab High-Risk Patients
Alemtuzumab, tacrolimus, mycophenolate mofetil and steroids; High risk patients: Panel reactive antibody ≥ 20% or re-transplant or African American
|
doustny
Inne nazwy:
doustny
Inne nazwy:
Intravenous (IV)
Inne nazwy:
IV and/or oral
|
Aktywny komparator: Conventional High-Risk Patients
Rabbit anti-thymocyte globulin, tacrolimus, mycophenolate mofetil and steroids; High risk patients: Panel reactive antibody ≥ 20% or re-transplant or African American
|
doustny
Inne nazwy:
doustny
Inne nazwy:
IV and/or oral
IV
Inne nazwy:
|
Eksperymentalny: Alemtuzumab Low- Risk Patients
Alemtuzumab, tacrolimus, mycophenolate mofetil and steroids; Low risk patients: Panel reactive antibody < 20% and first transplant and non-African American
|
doustny
Inne nazwy:
doustny
Inne nazwy:
Intravenous (IV)
Inne nazwy:
IV and/or oral
|
Aktywny komparator: Conventional Low-Risk Patients
Basiliximab, tacrolimus, mycophenolate mofetil and steroids; Low risk patients: Panel reactive antibody < 20% and first transplant and non-African American
|
doustny
Inne nazwy:
doustny
Inne nazwy:
IV and/or oral
IV
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Patient Incidence of Biopsy-confirmed Acute Rejection (BCAR) at 6 Months
Ramy czasowe: 6 months
|
A BCAR is a suspected new rejection w/in 6 mos. of skin closure, confirmed by Banff Grade ≥1A assigned by a pathologist. The Banff 97 classification system is used for interpreting histology of allograft biopsies, including Mild (1A/1B), Moderate (2A/2B) & Severe (3). Kaplan Meier analysis was used to estimate % of pts. w/event. Patients w/no event at time of scheduled visit or whose 1st event was after premature discontinuation of study drug/tacrolimus were censored on the scheduled day of a) assessment, b) of premature treatment discontinuation or c) last evaluation, whichever came 1st. |
6 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Overall Patient Incidence of BCAR
Ramy czasowe: End of Study (36 months)
|
Overall patient incidence of BCAR is defined as a suspected new rejection at any time following skin closure confirmed by a Banff Grade ≥ 1A as assigned by a local pathologist. Incidence is reported as the percentage of patients with BCAR. The Banff 97 scale is a classification system for interpreting histology of allograft biopsies. The grades range from Mild (1A & 1B) to Moderate (2A & 2B) to Severe (3). End of Study was defined as the last day of evaluation and could have included bivariate assessments after 36 months. |
End of Study (36 months)
|
Efficacy Failure
Ramy czasowe: End of Study (36 months)
|
Efficacy Failure is a composite measure of biopsy confirmed acute rejection, graft loss and death. Data is reported as the percentage of patients with Efficacy Failure. End of Study was defined as the last day of evaluation and could have included bivariate assessments after 36 months. |
End of Study (36 months)
|
Clinically Treated Acute Rejection
Ramy czasowe: End of Study (36 months)
|
Clinically treated acute rejection is defined as patient incidence of any rejection (suspected or otherwise) for which treatment was provided. Data is reported as the percentage of patients with Clinically Treated Acute Rejection. End of Study was defined as the last day of evaluation and could have included bivariate assessments after 36 months. |
End of Study (36 months)
|
Time to First BCAR
Ramy czasowe: End of Study (36 months)
|
Time to first BCAR is defined as the number of days from skin closure to the first episode of BCAR. End of Study was defined as the last day of evaluation and could have included bivariate assessments after 36 months. |
End of Study (36 months)
|
Graft Survival at 12 Months
Ramy czasowe: 12 months
|
Graft survival is defined as no graft loss (re-transplant, return to dialysis for more than 30 days or death) with 12 months of skin closure. Kaplan Meier analysis was used to estimate percentage of patients with event. Patients with no event by the time of the scheduled visit or whose first event was after premature discontinuation of randomized study drug or tacrolimus were censored on the scheduled day of assessment, on the day of premature treatment discontinuation or last evaluation day, whichever came first. |
12 months
|
Overall Graft Survival
Ramy czasowe: End of Study (36 months)
|
Overall graft survival is defined as not having graft loss (re-transplant, return to dialysis for more than 30 consecutive days, or death) at any time following skin closure. Data is reported as the percentage of patients with Overall Graft Survival. End of Study was defined as the last day of evaluation and could have included bivariate assessments after 36 months. |
End of Study (36 months)
|
Patient Survival at 12 Months
Ramy czasowe: 12 months
|
Patient survival is defined as not dead within 12 months after skin closure. Kaplan Meier analysis was used to estimate percentage of patients with event. Patients with no event by the time of the scheduled visit or whose first event was after premature discontinuation of randomized study drug or tacrolimus were censored on the scheduled day of assessment, on the day of premature treatment discontinuation or last evaluation day, whichever came first. |
12 months
|
Overall Patient Survival
Ramy czasowe: End of Study (36 months)
|
Overall patient survival is defined as not dead at any time following skin closure. Data is reported as the percentage of patients with Overall Patient Survival. End of Study was defined as the last day of evaluation and could have included bivariate assessments after 36 months. |
End of Study (36 months)
|
Renal Function Abnormalities Based on Creatinine Clearance
Ramy czasowe: 1 month and End of Study (36 months)
|
Increases in creatinine clearance usually indicates an improvement. Change in creatinine clearance from month 1 was calculated. Change from 1 month is calculated by month 36 - month 1. |
1 month and End of Study (36 months)
|
Renal Function Abnormalities Based on Serum Creatinine
Ramy czasowe: 1 month and End of Study (36 months)
|
Decrease in serum creatinine usually indicates an improvement. Change in creatinine clearance from month 1 was calculated. Change from 1 month is calculated by month 36 - month 1. |
1 month and End of Study (36 months)
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Central Contact, Astellas Pharma Global Development
Publikacje i pomocne linki
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Środki przeciwinfekcyjne
- Inhibitory enzymów
- Środki przeciwnowotworowe
- Środki immunosupresyjne
- Czynniki immunologiczne
- Środki przeciwnowotworowe, immunologiczne
- Środki przeciwbakteryjne
- Antybiotyki, Przeciwnowotworowe
- Środki przeciwgruźlicze
- Antybiotyki, Przeciwgruźlicze
- Inhibitory kalcyneuryny
- Takrolimus
- Kwas mykofenolowy
- Bazyliksymab
- Tymoglobulina
- Serum antylimfocytarne
- Alemtuzumab
Inne numery identyfikacyjne badania
- 20-04-003
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na takrolimus
-
Ain Shams UniversityNational Hepatology & Tropical Medicine Research InstituteZakończony